{"entity":{"id":"nct00569127","kind":"trial","name":"Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor","aka":[],"tldr":"A phase 3 trial of bevacizumab (glioblastoma use) in colorectal cancer, run by National Cancer Institute (NCI), active but no longer recruiting.","summary":"Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor is a phase 3, randomised interventional study registered as NCT00569127 by National Cancer Institute (NCI), with a registry enrolment figure of 427 participants, started 2007-12-01 and due to reach its primary completion in 2015-01-01. Interventions recorded: Bevacizumab; Laboratory Biomarker Analysis; Octreotide Acetate; Recombinant Interferon Alfa-2b. Conditions listed: Colorectal Neuroendocrine Tumor G1; Gastric Neuroendocrine Tumor G1; Neuroendocrine Neoplasm; Neuroendocrine Tumor; Neuroendocrine Tumor G2. Primary outcome: Central Review-based Progression-Free Survival. Colorectal eligibility wording from the registry: \"* Metastatic colorectal carcinoid; patients with metastatic cecal or appendiceal carcinoid tumor are not eligible unless the tumors fit into one of the other high-risk categories (a, b, or c above)\". Sites: United States. Results were posted on ClinicalTrials.gov in 2016; the figures recorded here are the registry's, not a publication's.","status":"active","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT00569127","url":"https://clinicaltrials.gov/study/NCT00569127"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","colon-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["bevacizumab-glioma"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT00569127","phase":"3","setting":"Phase III Prospective Randomized Comparison of Depot Octreotide Plus Interferon Alpha Versus Depot Octreotide Plus Bevacizumab (NSC #704865) in Advanced, Poor Prognosis Carcinoid Patients","sponsor":"National Cancer Institute (NCI)","started":"2007-12-01","startedType":"actual","yearReported":2016,"enrolled":427,"enrolledBasis":"registry","outcomes":[{"endpoint":"Central Review-based Progression-Free Survival","primary":true,"unit":"months","arms":[{"name":"Octreotide, Bevacizumab","n":200,"value":16.6,"note":"95% CI 12.9 to 19.6; Figures from the ClinicalTrials.gov results section (first posted 2016-04-28), not from a publication"},{"name":"Octreotide, Interferon Alpha-2b","n":202,"value":15.4,"note":"95% CI 9.6 to 18.6"}],"hr":0.93,"ci":[0.73,1.18],"p":"0.55","source":"https://clinicaltrials.gov/study/NCT00569127?tab=results"},{"endpoint":"Overall Survival","unit":"months","arms":[{"name":"Octreotide, Bevacizumab","n":200,"value":35.2,"note":"95% CI 33.1 to 42.8; Figures from the ClinicalTrials.gov results section (first posted 2016-04-28), not from a publication"},{"name":"Octreotide, Interferon Alpha-2b","n":202,"value":47.3,"note":"95% CI 35.8 to 52.6"}],"source":"https://clinicaltrials.gov/study/NCT00569127?tab=results"}]},"route":"/trials/nct00569127/","neighbours":{"cancer":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"drug":[{"id":"bevacizumab-glioma","kind":"drug","name":"Bevacizumab (glioblastoma use)","route":"/drugs/bevacizumab-glioma/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}